Erschienen in:
28.08.2023 | Commentary
Double Trouble: The Challenge of Neuroprotection in Patients with Liver Cirrhosis and Atrial Fibrillation
verfasst von:
Taha Ahmed, Adrian W. Messerli
Erschienen in:
American Journal of Cardiovascular Drugs
|
Ausgabe 6/2023
Einloggen, um Zugang zu erhalten
Excerpt
The prevalence of liver cirrhosis (LC) continues to climb, primarily driven by increased alcohol consumption, aging hepatitis C population, and most importantly, the obesity epidemic. Resultant to this, clinicians are now increasingly managing complex patients with decompensated liver cirrhosis with concomitant atrial fibrillation, acute coronary syndrome, and severe valvular heart disease [
1,
2]. While treating these commonly coexistent disorders, most practitioners are well aware of bleeding risks in patients with LC. However, it is important to acknowledge that these patients also have a markedly increased risk of thrombosis, and anticoagulation or antiplatelet therapy may be advised for cardio- or neuro-protection. …